PubMed

Beta-cell response during a meal test: a comparative study of incremental doses of repaglinide in type 2 diabetic patients.

Cozma LS, Luzio SD, Dunseath GJ, Underwood PM, Owens DR.

Diabetes Care. 2005 May;28(5):1001-7.PMID: 15855557 [PubMed - indexed for MEDLINE]Related articlesFree article

Comparison of the effects of three insulinotropic drugs on plasma insulin levels after a standard meal.

Cozma LS, Luzio SD, Dunseath GJ, Langendorg KW, Pieber T, Owens DR.

Diabetes Care. 2002 Aug;25(8):1271-6.PMID: 12145220 [PubMed - indexed for MEDLINE]Related articlesFree article

Increased prandial insulin secretion after administration of a single preprandial oral dose of repaglinide in patients with type 2 diabetes.

Owens DR, Luzio SD, Ismail I, Bayer T.

Diabetes Care. 2000 Apr;23(4):518-23.PMID: 10857945 [PubMed - indexed for MEDLINE]Related articlesFree article

Modification of beta-cell response to different postprandial blood glucose concentrations by prandial repaglinide and combined acarbose/repaglinide application.

Rosak C, Hofmann U, Paulwitz O.

Diabetes Nutr Metab. 2004 Jun;17(3):137-42.PMID: 15334790 [PubMed - indexed for MEDLINE]Related articles

Optimizing insulin secretagogue therapy in patients with type 2 diabetes: a randomized double-blind study with repaglinide.

Schmitz O, Lund S, Andersen PH, Jønler M, Pørksen N.

Diabetes Care. 2002 Feb;25(2):342-6.PMID: 11815507 [PubMed - indexed for MEDLINE]Related articlesFree article

Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes.

Lund SS, Tarnow L, Frandsen M, Smidt UM, Pedersen O, Parving HH, Vaag AA.

Eur J Endocrinol. 2008 Jan;158(1):35-46.PMID: 18166815 [PubMed - indexed for MEDLINE]Related articlesFree article

Repaglinide versus nateglinide monotherapy: a randomized, multicenter study.

Rosenstock J, Hassman DR, Madder RD, Brazinsky SA, Farrell J, Khutoryansky N, Hale PM; Repaglinide Versus Nateglinide Comparison Study Group.

Diabetes Care. 2004 Jun;27(6):1265-70.PMID: 15161773 [PubMed - indexed for MEDLINE]Related articlesFree article

Repaglinide treatment amplifies first-phase insulin secretion and high-frequency pulsatile insulin release in Type 2 diabetes.

Hollingdal M, Sturis J, Gall MA, Damsbo P, Pincus S, Veldhuis JD, Pørksen N, Schmitz O, Juhl CB.

Diabet Med. 2005 Oct;22(10):1408-13.PMID: 16176204 [PubMed - indexed for MEDLINE]Related articles

Compared to glibenclamide, repaglinide treatment results in a more rapid fall in glucose level and beta-cell secretion after glucose stimulation.

Abbink EJ, van der Wal PS, Sweep CG, Smits P, Tack CJ.

Diabetes Metab Res Rev. 2004 Nov-Dec;20(6):466-71.PMID: 15386823 [PubMed - indexed for MEDLINE]Related articles

Enhancement of early- and late-phase insulin secretion and insulin sensitivity by the combination of repaglinide and metformin in type 2 diabetes mellitus.

Rudovich NN, Leyck Dieken MG, Rochlitz H, Pfeiffer AF.

Exp Clin Endocrinol Diabetes. 2004 Jul;112(7):395-400.PMID: 15239026 [PubMed - indexed for MEDLINE]Related articles

Repaglinide--prandial glucose regulator: a new class of oral antidiabetic drugs.

Owens DR.

Diabet Med. 1998;15 Suppl 4:S28-36. Review.PMID: 9868989 [PubMed - indexed for MEDLINE]Related articles

Repaglinide improves blood glucose control in sulphonylurea-naive type 2 diabetes.

Van Gaal LF, Van Acker KL, De Leeuw IH.

Diabetes Res Clin Pract. 2001 Sep;53(3):141-8.PMID: 11483229 [PubMed - indexed for MEDLINE]Related articles

Efficacy and safety of combination therapy: repaglinide plus metformin versus nateglinide plus metformin.

Raskin P, Klaff L, McGill J, South SA, Hollander P, Khutoryansky N, Hale PM; Repaglinide vs. Nateglinide Metformin Combination Study Group.

Diabetes Care. 2003 Jul;26(7):2063-8. Erratum in: Diabetes Care. 2003 Sep;26(9):2708. PMID: 12832314 [PubMed - indexed for MEDLINE]Related articlesFree article

Repaglinide is more efficient than glimepiride on insulin secretion and post-prandial glucose excursions in patients with type 2 diabetes. A short term study.

Rizzo MR, Barbieri M, Grella R, Passariello N, Barone M, Paolisso G.

Diabetes Metab. 2004 Feb;30(1):81-9.PMID: 15029102 [PubMed - indexed for MEDLINE]Related articlesFree article

Control of postprandial plasma glucose by an oral insulin product (HIM2) in patients with type 2 diabetes.

Kipnes M, Dandona P, Tripathy D, Still JG, Kosutic G.

Diabetes Care. 2003 Feb;26(2):421-6.PMID: 12547873 [PubMed - indexed for MEDLINE]Related articlesFree article

Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.

Robbins DC, Beisswenger PJ, Ceriello A, Goldberg RB, Moses RG, Pagkalos EM, Milicevic Z, Jones CA, Sarwat S, Tan MH.

Clin Ther. 2007 Nov;29(11):2349-64.PMID: 18158076 [PubMed - indexed for MEDLINE]Related articles

Randomized dose ranging study of the reduction of fasting and postprandial glucose in type 2 diabetes by nateglinide (A-4166).

Gribble FM, Manley SE, Levy JC.

Diabetes Care. 2001 Jul;24(7):1221-5.PMID: 11423506 [PubMed - indexed for MEDLINE]Related articlesFree article

A double-blind randomized comparison of meal-related glycemic control by repaglinide and glyburide in well-controlled type 2 diabetic patients.

Damsbo P, Clauson P, Marbury TC, Windfeld K.

Diabetes Care. 1999 May;22(5):789-94.PMID: 10332683 [PubMed - indexed for MEDLINE]Related articlesFree article

Pharmacology and tolerability of a single dose of exenatide in adolescent patients with type 2 diabetes mellitus being treated with metformin: a randomized, placebo-controlled, single-blind, dose-escalation, crossover study.

Malloy J, Capparelli E, Gottschalk M, Guan X, Kothare P, Fineman M.

Clin Ther. 2009 Apr;31(4):806-15.PMID: 19446153 [PubMed - indexed for MEDLINE]Related articles

Control of postprandial hyperglycemia: optimal use of short-acting insulin secretagogues.

Carroll MF, Izard A, Riboni K, Burge MR, Schade DS.

Diabetes Care. 2002 Dec;25(12):2147-52.PMID: 12453952 [PubMed - indexed for MEDLINE]Related articlesFree article